-
Sanofi offers Ablynx billions of biobucks for nanobody partnership
cphi-online
July 21, 2017
Belgian biotech Ablynx just signed a potentially lucrative new deal with Sanofi that could be worth an eye-watering €2.4 billion, although just €23 million of that comes up front.
-
Emergent BioSolutions to buy Sanofi’s smallpox vaccine business for $125m
pharmaceutical-technology
July 18, 2017
US-based Emergent BioSolutions has entered an agreement to buy the ACAM2000, smallpox vaccine business of French pharmaceutical company Sanofi for up to $125m.
-
Amid dustup over taxpayer-funded research, Sanofi executive says it never rejected a Zika vaccine fa
fiercepharma
July 17, 2017
After taking a beating in countless press reports over its Zika vaccine partnership with the U.S. Army, Sanofi is hoping to clear the air. In a series of letters to a U.S. Army official and U.S. senators, executives said Sanofi never rejected a fair prici
-
Sanofi gets a flu vaccines booster with $650M-plus Protein Sciences buy
fiercepharma
July 14, 2017
Twice over the last year, Sanofi has come up short in high-stakes attempts at top M&A prospects. Now, the drugmaker has finally bagged an acquisition, though not on the scale of its runs for Medivation or Actelion.
-
Sanofi to acquire Protein Sciences
cphi-online
July 13, 2017
Acquisition adds recombinant-based influenza vaccine to Sanofi Pasteur's portfolio.
-
Sanofi agrees to buy Protein Sciences for $750m
pharmaceutical-technology
July 13, 2017
Sanofi has entered an agreement to acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, Connecticut, US.
-
Sanofi $750m acquisition gives it edge in flu vacccine market
pharmaphorum
July 12, 2017
Sanofi is to buy the vaccines biotech Protein Sciences in a deal worth up to $750 million, after missing out on bigger acquisitions.
-
Sanofi and Regeneron announce approval of Kevzara to treat rheumatoid arthritis in the European Unio
biospectrumasia
June 30, 2017
Kevzara is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R) and blocks pro-inflammatory IL-6 mediated signaling
-
Sanofi and Regeneron announce EC approval of Kevzara?(sarilumab)
expressbpd
June 28, 2017
It is used to treat adult patients with moderately to severely active rheumatoid arthritis in the European Union
-
Sanofi, Gilead eyeing the takeover of Tesaro
biospectrumasia
June 14, 2017
The company that acquires Tesaro will get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
